key: cord-0310226-aqliz0tl
authors: Meziani, Lydia; Robert, Charlotte; Classe, Marion; Da Costa, Bruno; Mondini, Michele; Clemenson, Céline; Mordant, Pierre; Ammari, Samy; Le Goffic, Ronan; Deutsch, Eric
title: Low doses of radiation increase the immunosuppressive profile of lung macrophages during viral infection and pneumonia
date: 2020-10-14
journal: bioRxiv
DOI: 10.1101/2020.05.11.077651
sha: 83f8778f715c79121ccd50ab841976db080dd9da
doc_id: 310226
cord_uid: aqliz0tl

Severe pneumonia and acute respiratory distress syndrome (ARDS) have been described in patients with severe COVID-19. Recently, early clinical data reported the efficacy of low doses of radiation therapy (RT) in the treatment of ARDS in patients with severe COVID-19. However, the involved mechanisms remained unknown. Here, we used airways-instilled lipopolysaccharide (LPS) and influenza virus (H1N1) as murine models of pneumonia, and Tolllike receptor (TLR)-3 stimulation in human lung macrophages. Low doses RT (0.5-1 Gy) decreased LPS induced pneumonia, and increased the percentage of Nerve- and Airway-associated Macrophages (NAMs) producing IL-10. During H1N1 viral infection, we observed decreased lung tissue damage and immune cell infiltration in irradiated animals. Low doses RT increased IL-10 production by infiltrating immune cells into the lung. Irradiation of TLR-3 ligand-stimulated human lung macrophages ex vivo increased IL-10 secretion and decreased IFNγ production in the culture supernatant. The percentage of human lung macrophages producing IL-6 was also decreased. Our data highlight one of the mechanisms by which low doses RT regulate lung inflammation and skew lung macrophages towards an anti-inflammatory profile. These data provide the preclinical rationale for the use and for the optimization of low doses RT in situations such as COVID-19-induced ARDS.

I N S E R M , C E A , O r s a y ,

The COVID-19 pandemic is responsible for more than one million deaths and 37.39 million cases worldwide as of October 12, 2020. The responsible agent, SARS-CoV-2, is an enveloped RNA virus of the Coronaviridae virus family. Human-to-human transmission occurs through respiratory droplets or contaminated surfaces (1) . The average incubation period is 5 days, with a range of 1 to 14 days. Most patients present mild respiratory tract infections, most commonly characterized by fever (82%) and cough (81%). Severe pneumonia and acute respiratory distress syndrome (ARDS) have been described in 14% of the reported cases, and the overall mortality is

Irradiation has a direct effect on macrophage activation, depending on time, dose, and subpopulations. In the tumor stroma, high doses of IR (> 8Gy) promote anti-inflammatory activity of macrophages (16) and low doses (< 2Gy) alone or combined with immunotherapy induce proinflammatory activity of macrophages (17, 18) . Within the lung, irradiation at high dose (16Gy) affects the phenotype of alveolar and interstitial macrophages differently, resulting in distinct local cytokine and chemokine microenvironments in the tissue and alveoli.

Interestingly, we have observed a difference between lung sub compartments in response to fibrogenic irradiation dose (16Gy) with an immune response first in the parenchyma, then in the alveolar compartment (19) .

In the present study, using Lipopolysaccharide (LPS), influenza A PR8 virus (H1N1) or Toll-like receptor 3 (TLR3) ligand Poly(I:C) as inductors of inflammation (20) , and low doses of RT as a potential treatment, we investigated whether RT could be involved in counteracting lung inflammation through IL-10 production.

To investigate whether low doses of RT protect mice from lung inflammation, we treated mice with sublethal doses of LPS by intratracheal administration over two consecutive days. Six hours after the second intratracheal administration, mice were irradiated at the whole thorax at 0.5 or 1

Gy and underwent Computed tomography (CT) imaging at lung level at several time points after whole thorax irradiation. LPS administration significantly increased lung density at 96 hours (post administration of the first dose of LPS) compared to PBS control, suggesting the 6 development of an inflammatory process in the lungs (Fig. 1A) . Interestingly, irradiated lungs at 1Gy had a reduced tissue density compared to the LPS group, suggesting that a low dose of 1 Gy protects mice from LPS-induced lung inflammation. Furthermore, histopathological analysis showed a decrease in parenchyma destruction (Fig. 1B) and a trend towards a reduced peribronchial infiltration in irradiated lungs at 1Gy (Fig. 1C) .

NAMs act as a main player to counteract lung inflammation via IL-10 secretion (14) . We therefore hypothesized that, in the preclinical LPS pneumonia model, low doses of RT could stimulate IL-10 secretion by NAMs. Our results showed that LPS-induced lung inflammation is associated with a trend towards an increased percentage of NAMs producing IL-10 ( Fig. 1D) .

Interestingly, low doses of RT further increased the percentage of NAMs producing IL-10 compared to the non-irradiated group. Using a Poly(I:C)-induced inflammation model, we confirmed that low doses of RT induced a greater increase of IL-10 + NAMs percentage compared to PBS control (Fig.1E ).

To evaluate the effect of low-dose RT on a viral pneumonia model, we treated mice with a lethal dose of PR8 virus (a murine-adapted influenza strain) by intranasal instillation. Two days after the instillation, mice were irradiated at the whole thorax at 0.5, 1Gy or treated with a single dose of dexamethasone. Histopathological analysis of the lung showed that, four days after viral infection, PR8 virus induced a significant increase in both emphysema/alveolar septum rupture and the thickening of the alveolar septum compared to the PBS group (Fig. 2, A and B) . Low doses of RT as well as dexamethasone decreased the emphysema/alveolar septum rupture (p=0.0001 for 0.5Gy and p=0.06 for both 1Gy and dexamethasone) and a slight, even if notsignificant, reduction of the thickening of the alveolar septum was observed in low RT and dexamethasone groups compared to the PR8 condition. At eight days post-infection, we observed a significant increase in both vascular congestion and red blood cell extravasation in the PR8 group compared to the PBS group (Fig. 2, C and D) . Interestingly, low doses of RT or dexamethasone did not exacerbate vascular congestion and red blood cell extravasation compared to the PR8 group. More interestingly, low doses of RT and dexamethasone induced a downward trend in both vascular congestion and red blood cell extravasation compared to the PR8 group.

The analysis of immune cell infiltrate in infected lungs showed that 0.5Gy of RT induced a decreased number of CD45 + cells (Fig. 2E) 

Flow cytometry analysis three days after PR8 infection showed that 0.5Gy of RT, in contrast to dexamethasone treatment, induced a significant increase in the percent of NAMs producing IL-10 ( Fig. 3A) . The percent of NAMs producing both IFNγ and IL-6 significantly decreased after PR8 infection compared to the PBS group, and it was neither affected by low doses of RT nor dexamethasone. Similarly, low doses of RT induced an increase in the percent of both AMs and neutrophils producing IL-10 compared to the other group (Fig. 3, B and C) . The percents of AMs and neutrophils producing IFNγ and IL-6 were not affected by the different treatments. In agreement with data obtained with LPS and poly(I:C) models, our data clearly show that low doses of RT during viral infection stimulate murine NAMs (as well as alveolar macrophages and neutrophils) to produce IL-10.

We then aimed to confirm whether low doses of RT could stimulate human lung macrophages to produce IL-10. Sixteen hours after human macrophage irradiation, culture supernatants were analyzed for cytokine secretion and human macrophage activation was analyzed by flow cytometry. The quantification of the supernatants showed that low doses of RT decreased IFNγ secretion and increased IL-10 secretion by Poly(I:C)-stimulated human lung macrophages compared to non-irradiated Poly(I:C)-stimulated ones (Fig. 4A) . The levels of IFNα, TNFα, IL-2 and IL-9 were not affected by the low doses of RT.

Subsequently, we performed flow cytometry analysis for human lung macrophages and observed an increase in the percentage of human lung macrophages producing IL-10 after low-dose irradiation of 0.5 Gy compared to other culture conditions (Fig. 4B) . Interestingly, the percentage of human lung macrophages producing IL-6 decreased after low-dose irradiation of 0.5 and 1 Gy compared to non-irradiated human lung macrophages (Fig. 4C ).

Finally, we evaluated the impact of low doses of RT on viral load in the lung. Four days after PR8 infection, broncho-alveolar lavage fluid from infected animals, were analyzed for the measurement of the viral titers. Our results indicated that low doses of RT as well as dexamethasone treatment have no effect on virus levels in the lungs (Fig. 5) .

In the present study, we described the role of low-dose RT in : 1-protecting mouse lungs from inflammation; 2-further stimulating the production of anti-inflammatory cytokine IL-10 by Interestingly, low dose RT (0.5 Gy) affects the bone marrow-derived macrophage phenotype, however, this strongly depends on the microenvironment (21) . Furthermore, a decrease in IL-1 secretion by macrophage cell lines after low doses of RT (0.5 and 0.7Gy) has been reported and LPS-induced TNF production was suppressed in 0.5Gy-irradiated RAW264.7 (22, 23) .

Accordingly, our results showed that human lung macrophages were affected by low doses of RT (0.5 and 1Gy) in vitro. Irradiated human lung macrophages decreased IFNγ production and increased IL-10 secretion. Furthermore, the percentage of human lung macrophages producing IL-10 increased after low doses of RT, while the percentage of human lung macrophages producing IL-6 decreased after exposure to inflammatory stimuli. Our data demonstrates that low doses of RT are involved in limiting the inflammatory response in favor of an anti-inflammatory response. In preclinical pneumonia models, tissue resident NAMs have been reported to robustly respond to inflammatory stimuli early during infection and to be the main negative regulators of inflammation in the lung via IL-10 production as a potential mechanism (14) . Similarly, our data confirmed the production of IL-10 by NAMs after Poly(I:C), LPS and PR8 influenza virus infection. Furthermore, we observed that a low dose of RT protects mice from lung inflammation, does not exacerbate lung tissue damages and decreases immune cell infiltration.

Whether or not the same NAMs that have been described in mice exist in human lungs with the same immunosuppressive function is not yet defined. Our data from in vitro -cultured human lung macrophages are not sufficient to answer this question and further immunohistological/cytofluorimetric analyses of human lung tissue are required.

In pneumonia, several old clinical studies have reported the effectiveness of low doses of RT (5-7). However, after the onset of effective antimicrobial agents, the use of IR in the treatment of patients has been discontinued and the involved mechanism remained unknown. Following the excess death toll related to the COVID-19 pandemic, some radiation oncologists suggested the use of low doses of RT to treat COVID-19 + patients suffering from ARDS (24-28), even if this raised some criticism, (29-32) given the uncertainties regarding a potential viral flare-up or an increase in lung tissue damage. In the absence of preclinical data, the scientific community is puzzled between the risks associated with a whole lung irradiation (acute worsening of the patients, and the immediate intrinsic risk of ARDS (14) . Our results obtained using PR8 influenza pneumonia model indicate that low doses of RT have no effect, neither on the AM population nor on viral expansion, suggesting that the use of low doses of RT would not negatively affect these parameters in viral pneumonias.

Our data show that low doses of RT decrease the tissue damages in the infected mice, and will contribute to define the optimal radiation dose to be used in the clinic, which is the minimal dose to induce a maximal impact on macrophage reprogramming without tissue damages, our data suggest that the 0.5-1Gy range should be considered clinically. In line with our data, several clinical studies including COVID-19 presenting pneumonia patients with advanced age or comorbidities reported an absence of acute toxicity after whole thorax low doses of RT (8, 9) . In these clinical studies, the authors reported an improvement in the respiratory function of the patients in the hours following low doses of RT with a marked improvement on the CT scan around 7 days after RT. These observations are in line with the kinetics of our observations. In summary, in line with the recent clinical data, the present study suggests that a single low-dose chest irradiation could be an efficient strategy to resolve human lung inflammation in pneumonia. Low doses of RT induce human lung macrophage reprogramming, in particular the production of the immunosuppressive IL-10 cytokine and the suppression of the inflammatory signals (IFNγ), which could be one of the mechanisms by which low doses of RT protect from human pneumonia (Fig. 6) . Our data highlight the effect and good tolerance of low doses of RT on both human and murine macrophage reprogramming and the positive regulation of lung inflammation. Our findings are in agreement with the initial clinical data released from two out of the current 14 activated clinical trials worldwide evaluating chest RT for COVID patients and contribute to justifying the use of RT in this very unusual non-cancer setting. Of note, the radiation doses used empirically in these clinical trials were not uniform; we do believe that carefully defining the lowest as possible effective dose is a major challenge at the heart of the current controversy and our data underscore the fact that doses superior to 1Gy are nonnecessary. These data provide the preclinical rational for both use and safety of low doses of RT in situations such as COVID-19-induced ARDS.

All patients signed an informed consent allowing the use of their surgical specimen for research purposes. The database was declared to the National Board for Informatics and Freedom 

Six hours after the second administration of LPS or Poly(I:C), the mice were immobilized by anesthesia (2% isoflurane) and locally irradiated at the thorax using a Varian Tube NDI 226 (Xray machine; 250 kV, tube current:15 mA, beam filter: 0.2 mm Cu), with a dose rate of 1.08

Gy·min−1. A single dose of 0.5 or 1 Gy was locally delivered to the whole thorax.

A single dose of 10mg/kg of dexamethasone (Dexamethasone Mylan 4 mg/1ml, solution for injection, lot n°200147, Mylan) was administered to the mice by intraperitoneal injection.

Mice underwent CT scan at lung level. During scanning, mice were immobilized by anesthesia (2% isoflurane). ImageJ software was used to quantify lung density on axial slices.

After animal euthanasia, the trachea was cannulated and secured using a silk suture. Cold PBS (500 L) was delivered and retrieved through the cannula. The lavage was repeated three times.

BAL fluid was used for virus titration.

BAL fluids viral titers were determined by standard plaque assay using Madin Darby canine kidney (MDCK) cells. Briefly, confluent monolayers of MDCK cells were infected with serially diluted BAL fluids. Infected monolayers were then covered with semisolid overlay medium (Avicel). 48 hours post-infection, cells were fixed using paraformaldehyde and lysis plaques were counted after crystal violet counterstaining.

Mouse lungs were fixed in 4% buffered ParaFormaldehye (PFA), paraffin embedded and then cut into 4 m sections. Lung sections were stained with hematoxylin-eosin-saffron (HES) and digitized using a slide scanner (Olympus VS120). 

Human and mouse lung tissues were digested using the Tumor Dissociation Kit (Miltenyi Biotec) for 30 minutes at 37°C and 1,500 rpm. The cells from the digested lung tissues were filtered using cell strainers (70 µm, Miltenyi Biotech) and used for subsequent experiments.

After washing with PBS and centrifugation (300 g, 4°C, 5 minutes), the human lung cells were suspended and cultured in DMEM-F12 supplemented with both fetal bovine serum (FBS; 10%) and penicillin/streptomycin (1%). Human lung cells were incubated in the indicated medium at 37°C and 5% CO 2 for 30 minutes. Then, the adherent cells (macrophages and monocytes) were washed using PBS, and the nonadherent cells were discarded. The adherent cells were incubated in fresh medium (DMEM-F12 containing 10% FBS and 1% penicillin/streptomycin) and stimulated with either Poly(I:C) at 1ug/mL or PBS (as control). Six hours after stimulation with the Poly(I:C), macrophages were irradiated using X-RAD320 (X-ray machine; 320 Kev, 4 mA) at a single dose of 0.5 or 1 Gy.

For cultured human lung macrophages staining: anti-CD169 (7-239) and anti-CD11c (REA618, Miltenyi Biotec) were used for membrane staining. Anti-IL-10 (REA842) and anti-IL-6 (REA1037, Miltenyi Biotec) were used for intracellular staining. 

Cytokine concentrations in culture supernatants from in vitro-activated human macrophage samples were profiled. The proteins in the supernatant were diluted to 4 mg/mL and analyzed using MACSplex Human cytokine (Miltenyi Biotec) and data were analyzed with FlowLogic 7.3

software.

Statistical analysis was performed using GraphPad Prism 7. One-way ANOVA was used to detect differences among multiple treatment groups. A p value equal to or less than 0.05 was considered significant (*p<0.05, **p<0.01, ***p<0.001, ****p<0.0001). Data are expressed as the mean±standard error of mean (SEM). 

China Novel Coronavirus Investigating and Research Team, A Novel Coronavirus from Patients with Pneumonia in China

Comparative therapeutic efficacy of remdesivir and combination lopinavir, ritonavir, and interferon beta against MERS-CoV

COVID-19: consider cytokine storm syndromes and immunosuppression

Elevated Calprotectin and Abnormal Myeloid Cell Subsets Discriminate Severe from Mild COVID-19

Radiation therapy of lobar pneumonia

Roentgen therapy of interstitial pneumonia

The effect of roentgen therapy on experimental virus pneumonia; on pneumonia produced in white mice by swine influenza virus

Low-Dose Whole-Lung Irradiation

Pneumonia: Short Course Results

Low-Dose Whole-Lung Radiation for COVID-19 Pneumonia, medRxiv

Low-dose radiotherapy for COVID-19 pneumonia treatment: case report, procedure, and literature review

Immunomodulation by ionizing radiation-impact for design of radio-immunotherapies and for treatment of inflammatory diseases

Tissue-resident macrophages

Two distinct interstitial macrophage populations coexist across tissues in specific subtissular niches

Identification of a nerveassociated, lung-resident interstitial macrophage subset with distinct localization and immunoregulatory properties

Pathological inflammation in patients with COVID-19: a key role for monocytes and macrophages

Blockade of tumor necrosis factor alpha signaling in tumor-associated macrophages as a radiosensitizing strategy

Molecular biology mechanisms in the radiation induction of pulmonary injury syndromes: interrelationship between the alveolar macrophage and the septal fibroblast

Low-dose irradiation programs macrophage differentiation to an iNOS + /M1 phenotype that orchestrates effective T cell immunotherapy

CSF1R inhibition prevents radiation pulmonary fibrosis by depletion of interstitial macrophages

Long-term activation of TLR3 by Poly(I:C) induces inflammation and impairs lung function in mice

Low-Dose Irradiation Differentially Impacts Macrophage Phenotype in Dependence of Fibroblast-Like Synoviocytes and Radiation Dose

Differential Effects of Irradiation with Carbon Ions and X-Rays on Macrophage Function

Low dose ionising radiation leads to a NF-κB dependent decreased secretion of active IL-1β by activated macrophages with a discontinuous dose-dependency

Is low dose radiation therapy a potential treatment for COVID-19 pneumonia?

The authors declare that they have no potential conflicts of interest related to this work. E.DEUTSCH reports grants and personal fees from ROCHE GENENTECH, grants from SERVIER, grants from ASTRAZENECA, grants and personal fees from MERCK SERONO, grants from BMS, grants from MSD, outside the submitted work